Single-cell transcriptomics reveals a low CD8+ T cell
8 Slides1.49 MB
Single-cell transcriptomics reveals a low CD8 T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma by Yu-Lu Peng, Long-Bin Xiong, Zhao-Hui Zhou, Kang Ning, Zhen Li, Ze-Shen Wu, Min-Hua Deng, Wen-Su Wei, Ning Wang, Xiang-Peng Zou, Zhi-Song He, Ji-Wei Huang, Jun-Hang Luo, Jian-Ye Liu, Nan Jia, Yun Cao, Hui Han, Sheng-Jie Guo, Pei Dong, Chun-Ping Yu, Fang-Jian Zhou, and Zhi-Ling Zhang J Immunother Cancer Volume 10(2):e004206 February 4, 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
scRNA-seq profiling of the tumor ecosystem in adjacent normal kidneys, pRCC and reRCC. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Identification and characterization of malignant cells in pRCC and reRCC. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Characteristics of infiltrating T cell in pRCC and reRCC. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Analysis of CD8 T cell transition states in pRCC and reRCC samples. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Expression pattern and clinical relevance of CAFs in RCC. (A) IHC staining of α-SMA (a marker of CAFs), in paired pRCC and reRCC samples from the validation cohort. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
CAFs induced CD8 T cells apoptosis via Gal1. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Gal1 inhibition reduces CD8 T cells apoptosis and enhances immunotherapy efficacy in RCC model. Yu-Lu Peng et al. J Immunother Cancer 2022;10:e004206 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
